Cadrenal Therapeutics (CVKD) Stock Rallies In After-Market Trading Ahead Of Regulatory Meeting

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) stock price increased last Friday during the after-hours trading session. After dropping 4.76% to close at $10.21 during the regular trading session, CVKD shares saw a 7.25% increase, finishing at $10.95. Cadrenal’s announcement of an important future meeting with regulatory authorities coincided with the stock price volatility.

Cadrenal Was In Plan To Meet The FDA Soon

Cadrenal (CVKD) announced at the end of the previous month that it will be interacting with the US Food and Drug Administration (FDA) in early September. Discussions about the tecarfarin clinical study for patients using Left Ventricular Assist Devices or LVADs will be the main topic of this Type-B meeting.

The meeting represents a critical milestone for the company as it seeks to advance tecarfarin toward a pivotal trial. During the discussions, Cadrenal will present its development program and strategies to the FDA, hoping to secure regulatory support for further clinical advancements.

Peer-Reviewed Research Highlights Tecarfarin’s Potential

In addition to the regulatory engagement, Cadrenal recently spotlighted a peer-reviewed manuscript published in the *Journal of Cardiac Failure*. The manuscript evaluated the relationship between the quality of VKA (Vitamin K Antagonist) management, time in therapeutic range (TTR), and clinical outcomes in LVAD patients.

Co-authored by Dr. Mandeep R. Mehra, the study concluded that while current LVAD pumps have significantly improved, there remains a need for better anticoagulant therapies. The findings suggest that newer VKAs, like tecarfarin, could reduce gastrointestinal bleeding and improve patients’ quality of life.

Tecarfarin’s Potential Role In LVAD Anticoagulation

Dr. Mehra, who chaired the ARIES-HM3 study, observed that tecarfarin, unlike warfarin, may offer superior anticoagulation management for LVAD patients. Tecarfarin’s reduced susceptibility to drug-drug interactions and kidney function changes makes it a promising candidate.

A secondary analysis of the ARIES-HM3 trial indicated that higher TTRs were associated with a 47% reduction in bleeding events. These promising results have given Cadrenal (NASD: CVKD) confidence that tecarfarin may better address LVAD patients’ anticoagulation needs.